HK1068798A1 - Antibodies for inhibiting blood coagulation and methods of use thereof - Google Patents

Antibodies for inhibiting blood coagulation and methods of use thereof

Info

Publication number
HK1068798A1
HK1068798A1 HK05101282.0A HK05101282A HK1068798A1 HK 1068798 A1 HK1068798 A1 HK 1068798A1 HK 05101282 A HK05101282 A HK 05101282A HK 1068798 A1 HK1068798 A1 HK 1068798A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
blood coagulation
native human
bind
methods
Prior art date
Application number
HK05101282.0A
Other languages
English (en)
Inventor
Jin-An Jiao
Hing C Wong
Esperanza Liliana Nieves
Luis A Mosquera
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/990,586 external-priority patent/US20030109680A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1068798A1 publication Critical patent/HK1068798A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467—Igs with modifications in the FR-residues only
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
HK05101282.0A 2001-10-29 2005-02-16 Antibodies for inhibiting blood coagulation and methods of use thereof HK1068798A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34330601P 2001-10-29 2001-10-29
US09/990,586 US20030109680A1 (en) 2001-11-21 2001-11-21 Antibodies for inhibiting blood coagulation and methods of use thereof
PCT/US2002/034727 WO2003037911A2 (fr) 2001-10-29 2002-10-29 Anticorps permettant d'inhiber la coagulation sanguine et procedes d'utilisation associes

Publications (1)

Publication Number Publication Date
HK1068798A1 true HK1068798A1 (en) 2005-05-06

Family

ID=26993414

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101282.0A HK1068798A1 (en) 2001-10-29 2005-02-16 Antibodies for inhibiting blood coagulation and methods of use thereof

Country Status (11)

Country Link
EP (1) EP1446157B1 (fr)
JP (1) JP4439914B2 (fr)
KR (1) KR100951432B1 (fr)
CN (1) CN100575364C (fr)
AT (1) ATE493148T1 (fr)
CA (1) CA2465325C (fr)
DE (1) DE60238782D1 (fr)
DK (1) DK1446157T3 (fr)
HK (1) HK1068798A1 (fr)
TW (1) TWI338009B (fr)
WO (1) WO2003037911A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030190705A1 (en) 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
AU2003225256B2 (en) * 2002-05-01 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
WO2004039842A2 (fr) * 2002-10-31 2004-05-13 Novo Nordisk A/S Anticorps humanises anti-facteur tissulaire
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
WO2004110363A2 (fr) * 2003-05-30 2004-12-23 Centocor, Inc. Procede pour inhiber la croissance tumorale avec des anticorps a facteurs anti-tissulaires
EP1644039B1 (fr) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions et procedes pour le traitement des troubles lies a la coagulation
EP1749536A1 (fr) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Stimulateurs activés du Facteur X et leur utilisation en tant qu'agents anti-hemorragiques pour l'usage topique
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN106084053B (zh) 2010-06-15 2020-01-17 根马布股份公司 针对组织因子的人抗体药物缀合物
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
GB201121513D0 (en) * 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
US20140296139A1 (en) 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
EP3103811A4 (fr) * 2014-02-03 2017-11-29 National Cancer Center Anticorps monoclonal anti-facteur tissulaire
SI3337817T1 (sl) * 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
CN107446047B (zh) * 2017-09-04 2020-08-11 山西省生物研究院有限公司 一种双功能性抗组织因子人源化抗体及其制备方法
US11672826B2 (en) 2018-08-30 2023-06-13 HCW Biologics, Inc. Methods of treating aging-related disorders
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
CA3108951A1 (fr) 2018-08-30 2020-03-05 HCW Biologics, Inc. Polypeptides chimeriques a chaine unique et leurs utilisations
CA3143035A1 (fr) 2019-06-21 2020-12-24 HCW Biologics, Inc. Polypeptides chimeriques a chaines multiples et leurs utilisations
JP2023519106A (ja) * 2020-02-11 2023-05-10 エイチシーダブリュー バイオロジックス インコーポレイテッド クロマトグラフィー樹脂およびその使用
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5869046A (en) * 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2231817T3 (es) * 1995-06-07 2005-05-16 Ortho-Mcneil Pharmaceutical, Inc. Anticuerpos del factor anti-tejido injertados a cdr y procedimientos de uso de los mismos.
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
CZ20003099A3 (cs) * 1998-02-25 2002-04-17 Lexigen Pharmaceuticals Corporation Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency

Also Published As

Publication number Publication date
TWI338009B (en) 2011-03-01
KR100951432B1 (ko) 2010-04-07
JP2006503541A (ja) 2006-02-02
DK1446157T3 (da) 2011-03-21
WO2003037911A2 (fr) 2003-05-08
EP1446157A4 (fr) 2005-12-28
JP4439914B2 (ja) 2010-03-24
CA2465325A1 (fr) 2003-05-08
WO2003037911A3 (fr) 2003-12-31
CN1599624A (zh) 2005-03-23
EP1446157B1 (fr) 2010-12-29
EP1446157A2 (fr) 2004-08-18
CA2465325C (fr) 2014-08-05
KR20050040844A (ko) 2005-05-03
CN100575364C (zh) 2009-12-30
DE60238782D1 (de) 2011-02-10
ATE493148T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
HK1068798A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
HK1029123A1 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
WO2004016750A3 (fr) Anticorps specifiques du recepteur fc$g(g)riib et procedes d'utilisation de ces anticorps
SG146696A1 (en) Humanized antibodies against vascular endothelial growth factor
WO2005110474A3 (fr) ANTICORPS SPÉCIFIQUES FcϜRIIB HUMANISÉS ET MÉTHODES D’UTILISATION
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
WO2002060955A3 (fr) Anticorps modifies et procedes d'utilisation
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
WO2005102387A3 (fr) Utilisation therapeutique des anticorps anti-cs1
RS20060234A (en) Fully human antibodies against human 4-1bb (cd137)
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
WO2005115452A3 (fr) Anticorps specifiques de fc$g(g)rii et methodes d'utilisation de ces anticorps
WO2003100033A3 (fr) Anticorps anti-$g(a)v$g(b)6
WO2003072036A3 (fr) Methodes therapeutiques utilisant des anticorps anti-cd22
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
WO2007120651A3 (fr) Utilisation et compositions pour le traitement de l'arthrite rhumatoïde juvénile
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
DK1194528T3 (da) Monoklonalt antistof mod faktor VII, hvilket antistof selv ved forekomst i molært overskud kun delvist inaktiverer faktor VII, samt fremgangsmåde til produktion af et sådant antistof
WO2007032804A3 (fr) Nouvelles utilisations pour une thérapie anti-ige
WO2006095180A3 (fr) Anticorps monoclonaux humanises contre le coronavirus associe a sras et traitement des patients atteints du syndrome respiratoire aigu severe (sras)
WO2004073649A3 (fr) Peptide clk et peptide slk
HUP0301804A2 (hu) Antitrombotikus ágensek
WO2004087734A3 (fr) Peptides stq

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF INVENTOR FROM JIAO, JIAN-AN TO JIAO, JIN-AN

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191029